Records containing: Lambert-Eaton Myasthenic Syndrome

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2025-03-26
  An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Pediatric Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), and in Pediatric and Adult Patients With Congenital Myasthenic Syndromes (CMSs)
• CLINICAL_TRIALS study record update · 2024-06-04
  Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
• CLINICAL_TRIALS study record update · 2022-06-07
  Barriers and Facilitators to Exercise for Individuals With Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome or Lambert-Eaton Myasthenic Syndrome in France: a Descriptive, Cross-sectional Study
• CLINICAL_TRIALS study record update · 2022-04-11
  Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)
• CLINICAL_TRIALS study record update · 2019-07-09
  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2018-12-24
  A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome
• CLINICAL_TRIALS study record update · 2017-07-11
  Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome
• CLINICAL_TRIALS study record update · 2016-07-20
  Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
• CLINICAL_TRIALS study record update · 2015-03-25
  ClinicalTrials.gov study NCT00004832